- Home
- FENC vs IMMX Comparison
FENC vs IMMX Comparison
Compare FENC & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | IMMX |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.3M | 306.2M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FENC | IMMX |
|---|---|---|
| Price | $8.03 | $8.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.00 | $13.00 |
| AVG Volume (30 Days) | 108.5K | ★ 735.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.67 | 14.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,538,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.69 | N/A |
| 52 Week Low | $4.68 | $1.34 |
| 52 Week High | $9.92 | $8.97 |
Technical Indicators
Market Signals| Indicator | FENC | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 64.51 |
| Support Level | $7.45 | $1.96 |
| Resistance Level | $8.09 | N/A |
| Average True Range (ATR) | 0.45 | 0.58 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 28.83 | 71.78 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.